Single-Dose , Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE 609 ( Cipargamin ) and Piperaquine

Daniel S. Stein, Jay Prakash Jain, Michael Kangas, Gilbert Lefèvre, Surendra Machineni, Paul Griffin, Jason Lickliter Novartis Institute for BioMedical Research, East Hanover, New Jersey, USA; Novartis Institute for BioMedical Research, Hyberabad, India; Novartis Institute for BioMedical Research, Basel, Switzerland; Integrated Quantitative Sciences, Hyderabad, India; Q-Pharm Pty. Ltd., QIMR Berghofer Medical Research Institute, Mater Health Services and Mater Research, and the University of Queensland, Brisbane, Queensland, Australia; Nucleus Network Ltd., Melbourne, Victoria, Australia